Efficacy and safety of alogliptin in subjects with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 study in mainland China, Taiwan and Hong Kong
机构：[1]The First Affiliated Hospital of the Fourth Military Medical University, Xi’an,[2]Shengjing Hospital of China Medical University, Shenyang,中国医科大学附属盛京医院中国医科大学盛京医院[3]First Affiliated Hospital Zhejiang University College of Medicine, Hangzhou,浙江大学医学院附属第一医院[4]The General Hospital of the People’s Liberation Army, Beijing,[5]Beijing Tongren Hospital, Beijing,首都医科大学附属北京同仁医院首都医科大学附属同仁医院[6]Peking Union Medical College Hospital, Beijing,[7]Affiliated Jingzhou Hospital Tongji Medical School, Wuhan, China,[8]Taipei Medical University Shuang Ho Hospital, Taipei, Taiwan,[9]Hong Kong Prince of Wales Hospital, Sha Tin, Hong Kong,[10]The General Hospital of the People’s Liberatino Army, Beijing, China.
第一作者机构：[1]The First Affiliated Hospital of the Fourth Military Medical University, Xi’an,
推荐引用方式(GB/T 7714)：
Ji Q.,Han P.,Li C.,et al.Efficacy and safety of alogliptin in subjects with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 study in mainland China, Taiwan and Hong Kong[J].DIABETOLOGIA.2013,56:S365-S365.
APA：
Ji, Q.,Han, P.,Li, C.,Lu, J.,Yang, J....&Pan, C..(2013).Efficacy and safety of alogliptin in subjects with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 study in mainland China, Taiwan and Hong Kong.DIABETOLOGIA,56,
MLA：
Ji, Q.,et al."Efficacy and safety of alogliptin in subjects with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 study in mainland China, Taiwan and Hong Kong".DIABETOLOGIA 56.(2013):S365-S365
医学